GROUPE FRANCOPHONE DES MYELODYSPLASIES

🇫🇷France

Country: 🇫🇷France

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)

Phase 1

Not yet recruiting

Conditions: Low-risk Myelodysplastic Syndromes

Interventions: Drug: Arsenic Trioxide (ATO)

First Posted Date: 2024-11-01

Last Posted Date: 2024-11-01

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 24

Registration Number: NCT06670222

Locations: 🇫🇷
CHU de Nice - Hôpital l'Archet - Service d'hématologie clinique, Nice, France
🇫🇷
Hôpital Saint Louis - Service Hématologie séniors, Paris, France
🇫🇷
Institut Gustave Roussy - Service d'hématologie, Villejuif, France

Oral Azacitidine Combined with Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes

Phase 1

Recruiting

Conditions: Untreated Myelodysplastic Syndrome

Interventions: Drug: Onureg + Venetoclax

First Posted Date: 2023-03-23

Last Posted Date: 2024-10-08

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 36

Registration Number: NCT05782127

Locations: 🇫🇷
CHU d'Amiens Picardie - Site sud, Amiens, France
🇫🇷
CHU d'Angers, Angers, France
🇫🇷
Hôpital Avicenne, Bobigny, France

and more 21 locations

Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)

Phase 2

Recruiting

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Venetoclax

First Posted Date: 2023-03-14

Last Posted Date: 2024-08-02

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 44

Registration Number: NCT05768711

Locations: 🇫🇷
CHU d'Angers, Angers, France
🇫🇷
CHU d'Amiens, Amiens, France
🇫🇷
Hôpital Avicenne, Bobigny, France

and more 20 locations

Venetoclax in Patients With MDS or AML in Relapse After AHSCT

Phase 1

Recruiting

Conditions: AML
MDS

Interventions: Drug: venetoclax + azacitidine +/- donor lymphocyte infusion

First Posted Date: 2022-02-07

Last Posted Date: 2024-08-05

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 55

Registration Number: NCT05226455

Locations: 🇫🇷
CHU d'Angers, Angers, France
🇫🇷
Hôpital Brabois, Vandœuvre-lès-Nancy, France
🇫🇷
IUCT Oncopole, Toulouse, France

and more 11 locations

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

Phase 1

Recruiting

Conditions: MDS
Myelodysplastic Syndromes

Interventions: Drug: Luspatercept Injection [Reblozyl]
Drug: Eprex

First Posted Date: 2022-01-06

Last Posted Date: 2024-08-02

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 150

Registration Number: NCT05181735

Locations: 🇫🇷
CHU Nantes - Hôtel Dieu, Nantes, France
🇫🇷
Clinique de l'Europe, Amiens, France
🇫🇷
CHR d'Orléans, Orléans, France

and more 34 locations

ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

Phase 2

Active, not recruiting

Conditions: MDS
AML

Interventions: Drug: ASTX727
Other: Donor Lymphocyte Infusions

First Posted Date: 2021-04-23

Last Posted Date: 2024-08-05

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 57

Registration Number: NCT04857645

Locations: 🇫🇷
CHU d'Angers - Service des maladies du sang, Angers, France
🇫🇷
CHU de Grenoble - Clinique Universitaire d'hématologie, Grenoble, France
🇫🇷
CHU d'Amiens Picardie - Site sud - Service hématologie clinique et thérapie cellulaire, Amiens, France

and more 9 locations

BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

Phase 2

Active, not recruiting

Conditions: Myelodysplastic Syndromes
Acute Myeloid Leukemia

Interventions: Drug: BST-236

First Posted Date: 2021-04-01

Last Posted Date: 2024-04-19

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 40

Registration Number: NCT04827719

Locations: 🇫🇷
CHU d'Angers, Angers, France
🇫🇷
CHU de Bordeaux Haut-Lévèque, Bordeaux, France
🇫🇷
CHU Amiens, Amiens, France

and more 14 locations

CPX-351 in Higher Risk Myelodysplastic Syndromes

Phase 1

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: CPX-351 in cohort A
Drug: CPX-351 in cohort B

First Posted Date: 2020-02-18

Last Posted Date: 2022-07-07

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 40

Registration Number: NCT04273802

Locations: 🇫🇷
CHU d'Amiens - Service d'hématologie clinique et thérapie cellulaire, Amiens, France
🇫🇷
Centre hospitalier Victor Dupouy - Service d'Hématologie, Argenteuil, France
🇫🇷
CHU d'Angers - Service des maladies du sang, Angers, France

and more 13 locations

IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

Phase 2

Active, not recruiting

Conditions: Leukemia Acute Myeloid
Myelodysplastic Syndromes

Interventions: Drug: AG-221

First Posted Date: 2018-11-16

Last Posted Date: 2024-04-19

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 68

Registration Number: NCT03744390

Locations: 🇫🇷
CHU de Bordeaux, Bordeaux, France
🇫🇷
Hôpital André Mignot, Versailles, LE Chesnay, France
🇫🇷
CH de la Cote Basque, Bayonne, France

and more 19 locations

Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

Phase 1

Conditions: Chronic Myelomonocytic Leukemia
Myelodysplastic Syndrome With Gene Mutation
Myeloproliferative Neoplasm
Acute Myeloid Leukemia With Gene Mutations

Interventions: Drug: APR-246
Drug: Azacitidine

First Posted Date: 2018-07-17

Last Posted Date: 2020-01-30

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 53

Registration Number: NCT03588078

Locations: 🇫🇷
Odile Beyne Rosy, Toulouse, France
🇫🇷
Hôpital Cochin/Service d'Hématologie, Paris, France
🇫🇷
Aspasia Stamatoullas, Rouen, France

and more 4 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy